Understanding the Role of TREM2 in Alzheimer’s Disease: Insights and Implications
Recent advances in Alzheimer’s disease research have spotlighted the TREM2 agonistic antibody AL002, which has shown promise in early-stage clinical trials. This phase 2 randomized trial aimed to assess the safety and efficacy of AL002 in patients with early Alzheimer’s disease, a disorder characterized by progressive cognitive decline. In the context of ongoing efforts to … Read more